Author:
Folkers-K. Langsjoen-P.
Langsjoen-P-H.
Source:
Biochem-Biophys-Res-Commun. 1992 Jan 15.
182(1). P 247-53.
Journal
Title: BIOCHEMICAL AND BIOPHYSICAL RESEARCH
COMMUNICATIONS.
Abstract:
Twenty years of international open and
seven double blind trials established the efficacy and safety
of coenzyme Q10 (CoQ10) to treat patients in heart failure. In
the U.S., ca. 20,000 patients under 65 years are eligible for
transplants, but donors are less than 1/10th of those
eligible, and there are many more such patients over 65, both
eligible and ineligible. We treated eleven exemplary
transplant candidates with CoQ10; all improved; three improved
from Class IV to Class I; four improved from Classes III-IV to
Class II; and two improved from Class III to Class I or II.
After CoQ10, some patients required no conventional drugs and
had no limitation in lifestyle. The marked improvement is
based upon correcting myocardial deficiencies of CoQ10 which
improve mitochondrial bioenergetics and cardiac performance.
These case histories, and very substantial background proof of
efficacy and safety, justify treating with CoQ10 patients in
failure awaiting transplantation.
